MedTrace Logo

Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy

NCT04542993 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2022-07-29

No results posted yet for this study

Summary

Administration of Zinc and resveratrol or double placebo for a period of 5 days and will be monitored for a 14 day period in covid-19 positive patients in an outpatient setting

Conditions

  • Covid19
  • SARS-CoV Infection

Interventions

DIETARY_SUPPLEMENT

Zinc Picolinate

Zinc Picolinate (50 mg PO TID x 5 days)

DIETARY_SUPPLEMENT

Resveratrol

Resveratrol 2 grams po BID x 5 days

DIETARY_SUPPLEMENT

Zinc Picolinate Placebo

Zinc Picolinate Matched Placebo PO TID x 5 days

DIETARY_SUPPLEMENT

Resveratrol Placebo

Resveratrol Matched Placebo PO BID x 5 days

Sponsors & Collaborators

  • Swedish Medical Center

    lead OTHER

Principal Investigators

  • Hank Kaplan, MD · Swedish Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-08
Primary Completion
2021-02-05
Completion
2021-02-05

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04542993 on ClinicalTrials.gov